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Abstract 
This study examined the types, nature and intensity of academia-industry interactions in Nigeria’s pharmaceutical 
innovation system. Eight (8) top-ranked universities offering Pharmacy as a course of study, 2 Pharmaceutical 
Research Institutes and 25 pharmaceutical firms were sampled for the study. Interactions are predominantly in 
the form of knowledge flow and consultancy, staff exchange/fellowship programmes as well as sponsored 
workshop participations. Intensity of interactions is limited as only 20% of pharmaceutical researchers from 
Universities and 7% from Research Institutes had strong interactions with Pharmaceutical firms, while only 4 
firms have strong interactions with the researchers. 
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1.0. Introduction 
Innovation has been identified as the basis for rapid industrial growth and competitiveness. Innovation Systems 
(1, 2, 3) constitute an analytical framework for understanding and evaluating the socioeconomic structure and 
innovativeness of nations. This approach which is largely based on the interactive learning theory of Lundvall 
underscores the importance of interactions among the agents within a system. The Innovation system framework 
therefore consists of analyzing the existence of actors in a given system (institutions, universities, industries, etc), 
their main competences and the interactions into innovation networks that occur among them. The framework is 
therefore a useful tool for measuring innovation success, constructing a more competitive and efficient 
innovation system by policy makers and other authorities within a virile NIS.  
   
Several empirical studies continue to show the essentiality of interactions among agents within a virile NIS as a 
determining factor for a robust innovation performance (3, 4, 5, 6). For example, (4) argue that knowledge 
interactions among firms, public research institutions and technology policy are key determinants of innovation 
success. Knowledge arising from University and Research Institutes’ Science and Technological researches 
significantly impact on the industrial sector through the production of prototypes, design of new processes and 
other products, and lowering of research and development (R&D) costs (4, 7). The Universities and public 
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Research Institutes (RI) also provide major inputs for industrial production processes in terms of human capital, 
either through the education of graduates, who become industry researchers or through personal mobility from 
the academic institutions to the firms (4). On the industry side, the extent of knowledge exploitation for economic 
development, within the context of academia-industry linkages, depends largely on internal capability of firms, 
the nature and intensity of interactions. Evidence from OECD show that many industries have developed the 
research capacities that are sometimes more advanced than that of the public sector. In addition to in-house R&D, 
industrial firms out-source R&D to Universities and RI through consultancy & contract research, joint research or 
training. Personnel mobility, conferences, informal contacts and commercialisation of intellectual property rights 
are other channels of interactions. Through these interactions academic researchers receive additional income, 
research fund, gain access to industry resources and an awareness of industry-related problems useful for further 
research. 
The relevance of academia-industry interactions to technological progress and economic development, especially 
in terms of stimulating technological advancement in the private sector, promoting industrial competitiveness and 
encouraging the generation of new products, processes and services should be of interest to emerging and 
developing economies. Nigeria, like many developing countries, still struggles to develop a strong NIS able to 
cope with the challenges of globalization and market competition as well as attain technological advancement 
and improve the well being of the citizenry. With a population of nearly 160million people (current projections) 
and about 60-70% of this figure living within the poverty line coupled with poor infrastructural facilities and a 
weak industrial base, the quest for a full-fledged NIS to drive all the sectors of the economy is of strategic 
importance. The need to increase productivity, achieve industrial competiveness and subsequently attain 
sustainable socioeconomic development is increasingly becoming important for Nigeria's survival as a nation. 
Policy interventions aimed at promoting and strengthening academia industry relations in order to maximise its 
advantages for economic development have become urgent and imperative in view of the prevailing poverty and 
poor human development indices. Several policy initiatives and many developmental strategies have been 
adopted to fasttrack Nigeria's economy within the context of NIS framework (8,9,10), but to what extent have 
academia-industry interactions impacted on Nigeria's economic development remains a relevant question.  
Studies of Nigeria’s NIS (11, 12, 8, 9, 10) revealed Nigeria's under-developed innovation system and weak 
research-industry interactions.  It was argued that labour conditions of employment and cost implications (in time 
and money) have hindered or disinclined Nigerian university professors from engaging in interactions that could 
lead to commercial ventures such as academic entrepreneurship and formation of spin-off companies (7). The 
general problems of the university system in Nigeria and the paucity of physical and knowledge infrastructures 
were also considered as obstacles to university industry interactions and the innovation process.  Furthermore, a 
baseline assessment of the pharmaceutical sector carried out by the Federal Ministry of Health in collaboration 
with WHO (13) appears not to take cognisance of any sectoral innovation development.  
The pharmaceutical subsector, a multibillion dollar industry, represents a huge potential for boosting Nigeria's 
economy and producing essential pharmaceuticals, especially drugs, to meet the healthcare needs of the nation 
and improve the quality of life of its populace. However, in the face of global competitiveness, drug resistance 
and emergence of new diseases the need to develop new drugs, particularly from indigenous raw materials and 
recipes, improve on existing ones with enhanced efficacy, precision in action, safety and quality becomes 
important. Although the capability to produce active pharmaceutical ingredients (API) of generic and specialised 
drugs is non-existent as at 2010 (14), more indigenous pharmaceutical firms are venturing into the market. It is 
important to formulate policies to build or strengthen the capacity of these firms to manufacture drugs from local 
materials. This will require the input of research knowledge and active collaboration with external sources of 
knowledge such as Universities and Research Institutes. The present study examines the current status of 
academia industry interactions in the Nigerian pharmaceutical innovation system with the objectives of assessing 
the nature and intensity of such interactions, identifies gaps and suggests policy directions.   
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 1.1 Brief Profile of Nigeria's Pharmaceutical sub-Sector
The Pharmaceutical industry is an important sub-sector of the manufacturing sector as it contributes 2% of GDP 
or US$7.396 billion PPP (N 1.109 trillion PPP). There are about 128 local drug manufacturers in Nigeria, which 
represent between 60- 70% of the total pharmaceutical manufacturing concerns in the West Africa subregion 
(14). The pharmaceutical manufacturing sub-sector has an aggregate investment of over N300 billion and 
employs over 600,000 people. Between 2000 and 2008, the sub-sector received foreign direct investment of 
about US$1.5bn. The domestic pharmacy market was worth about US$ 600million  in 2009 and was projected to 
grow substantially at about 12% annually to reach US$ 717 million by 2011 (14). The estimated market for 
prescription ethical pharmaceuticals is US$ 500 million and that for over the counter (OTC) pharmaceuticals 
about US$ 900 million. PMG-MAN estimates the market for biological products to be worth US$ 100 million 
according to (14) report on Nigeria's Pharmaceutical sector profile. Out of the 71 companies registered as active 
members of the Pharmaceutical Manufacturing Group in 2012 only eight (8) are listed on the Nigerian Stock 
Exchange. These attributes were major considerations in purposively selecting the subsector for the impact 
assessment of academia industry interactions.  
 2.0 State- of- the- Art 
2.1 Innovation Systems 
The innovation system approach emphasises interactions among knowledge institutions (universities and research 
institutions), firms and governments for innovation success. The role of universities and other research 
institutions were conceived in the 'linear model of innovation' to be limited to the creation and dissemination of 
knowledge, which is utilized occasionally in the production of goods and services or in design or process 
innovation. The recognition of this fact made governments of the industrialised countries to link universities to 
industrial innovation through the establishment of science parks, business incubation centres, public seed capital 
funds and other bridging institutions since the 1970s in order to enhance research-based, local economic 
development (15).  "Mode or Type 2" innovation concept viewed research to be more interdisciplinary and inter-
institutionally collaborative, encompassing the interaction of many more communities of researchers and other 
actors within any given research area. Innovation is no longer seen as a linear process but as a spiral mode 
operationalised through strategic networking between different actors at the national and international levels in 
multidisciplinary knowledge networks (16). The Mode 2 concept reflects the increased scale and diversity of 
sources for knowledge inputs required for scientific research. Subsequent developments in the innovation process 
recognise government action and legal frameworks as factors influencing academia-industry interactions.  
The Triple Helix concept emphasised increased interaction among institutional actors, with each actor assuming 
the role of the other such that universities engage in entrepreneurial tasks of marketing knowledge and creating 
companies while firms take on academic responsibilities (15). The interaction of academia, public research and 
industry is agreed to take place in an economic and policy environment (16). The Triple Helix theory connotes 
that universities have embraced economic and social development as a new mission without jettisoning her 
traditional engagements of teaching and research (17).  In accepting this new task, universities are said to become 
part of a coherent system that includes industry and government and underpins innovation and economic progress 
(17).  
Great attention is now shifting on exploiting the potential of the various forms of academia-industry linkages to 
accelerate research and technological development for sustainable development. Dwindling public funding for 
research plus increased competition for the available research funds have led to aggressive disposition of 
universities towards becoming entrepreneurial in seeking new sources of funding and capability for research, 
especially through university-industry linkages. Several studies have consequently showed an increasing level of 
academic commercial activities such as patenting, licensing, enterprise and spin-off creation (17, 16). Within the 
context of the entrepreneurial mission, academia-industry research collaborations have been found to be 
extremely important mechanisms for generating technological development (17). Other forms of interactions 
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such as joint scientific publications, joint research ventures, contract research and consultancies, training of firm 
staff, joint supervision of PhD and Masters Theses, staff exchange, formal and informal meetings have also 
increased (4). At the same time, several policy initiatives of governments worldwide are being introduced with 
increasing rapidity to promote academia involvement in technology transfer activities. This has led to 
developments in Europe, especially in OECD countries, where research capacities of firms have taken roots and 
are yielding greater R&D outputs than those of the academia.  
2.2 Academic Industry interactions 
Academia industry interaction, in the context of this study, is limited to "university-industry interaction" and 
"research institute-industry" interactions as defined by (16). Martin argued that research organisations engaged in 
basic, applied and development research play a significant role in knowledge production, and many of them are 
also engaged in interactions/linkages with the industry. Academia-industry interactions have since assumed an 
important role in the policy arena and become a veritable object of study in academic circles. Universities are 
increasingly being called upon to contribute to economic development and competitiveness and policy-makers 
have put in place initiatives aimed at increasing the rate of commercialization of university technology. Notably, 
policy-makers implemented laws that provide commercialization incentives to universities by granting them 
ownership of intellectual property arising from their research.  
Other policies encourage universities and firms to engage in partnerships and personnel exchange, for instance 
via university-industry centers or science parks. Finally, a third type of initiative seeks to build universities’ 
knowledge transfer capabilities by supporting recruitment and training of technology transfer staff. The subject 
matter keeps on expanding and is now known to embrace a wide range of modalities in the form of student 
placement schemes, staff exchanges, sabbatical staff engagements, consultancy services, continuing professional 
development, joint research and development, joint publications, informal meetings (including talks and 
communication), small enterprise development (including the creation of spin-offs for the commercialisation of 
R&D products and the development of consortia for collaborative R&D at the international level (4,16).   
Academic industry interactions are conceptualised as a means to bridge the perceived gap between science base 
and the productive sector which would allow the rapid transformation of knew knowledge into innovation. They 
are an important tool for making high education more relevant to employment as well as ease the entry into the 
labour market.  Collaborative engagement with industry may benefit academics’ research activities by 
establishing relationships with knowledge users and mobilizing resources that complement public research 
funding. In many disciplines, interaction between researchers and producers of technology underlies the progress 
of both science and technology in a mutually beneficial way.  
2.3 Academia industry interaction and Pharmaceutical innovation 
Case studies show that drug discovery is characterised by a high degree of public and private interaction in 
research. The pharmaceutical innovative process is reported to be a learning process with multiple points of 
public-private interaction as well as information feedback taking place along the whole innovative chain from 
drug discovery to market and back to drug discovery. Existing qualitative and quantitative evidence show a 
strong influence of academic research on pharmaceutical innovation. Reports show that 79% of US drug and 
medical patents originated from public science institutions, while firm-level interaction with public research was 
positively related to performance in drug delivery (18, 19). (20) showed that the pharmaceutical industry had the 
highest percentage of new products based on recent academic research. (21) reported that public research 
influenced new project ideas in the pharmaceutical industry more than in any other manufacturing industry. 
2.4 Nigeria NIS and pharmaceutical innovation 
 Pharmaceuticals are an integral component of health care systems globally. Pharmaceutical innovation is the 
discovery, development, production and delivery process that enhance the availability of medical products and 
people's access to them. Evidence from literature indicate little or no pharmaceutical innovation is taking place in 
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Africa since her capacity for pharmaceutical R&D and local drug production is among the lowest globally. This 
is responsible for the inability of many African countries to produce essential medicines for the teeming 
population daily confronted with poverty and a range of debilitating diseases. Several local and international 
initiatives have however been adopted by many African countries in the recent times to remedy the situation. 
In Nigeria, the thrusts of the National Drug Policy (1990) and (2005 revised) editions were to make available at 
all times medicines which are effective, affordable, safe and of good quality in all sectors of the health care 
system; improve the quality of health care through the rational use of medicines and boost local capacity for the 
manufacture and export of essential medicines (13). The revised 2005 Drug Policy set a 70% local essential drugs 
manufacturing target achievable over the 10 years following 2005 and also sought to promote pharmaceutical 
research and development of raw materials for the production, compounding and formulation of pharmaceutical 
products. The Presidential Forum on the Pharmaceutical Sector held in 2003 and the favourable 2005 Fiscal 
Policy were practical steps taken by Government to ensure that the local pharmaceutical industry becomes a 
major actor in providing good quality essential medicines and increase the vibrancy of the sector   for the 
improvement of the people's health. Meeting the healthcare needs of Nigerians for medicines on a sustainable 
basis will depend on a mix of many factors, including a robust S&T system, active production of drugs locally, 
strong pharmaceutical innovation and a vibrant NIS in the health sector.    
Local production of drugs, especially the essentials drugs, is identified as an important component of a long term 
solution to the provision of adequate health care in developing countries (14). The capacity to produce drugs to 
meet national health needs is argued to depend on building national capacity for innovation. Successful 
pharmaceutical innovation is the result of a complex web of interactions involving private and public research, 
development, teaching and healthcare delivery institutions, government ministries, regulatory authorities and 
other stakeholders (22). The new national STI policy (2010) recently adopted by the Government provides a 
suitable platform for attaining these goals since it aims to promote effective linkages and collaborations among 
knowledge institutions and industries engaged in health sector. It is designed to strengthen demand-driven R&D 
in natural and orthodox medicines as well as pharmaceutical research. The new STI policy is also fashioned to 
facilitate the development of biological diagnostic tools, vaccines and encourage R&D in alternative and 
molecular medicine. 
Weak academic-industry interaction is a common feature of Nigeria's NIS (8). Furthermore, baseline assessment 
report (13) and sector profile on the Nigerian pharmaceutical industry (14) were not explicit on any innovative 
performance in the sector. Although corruption, counterfeiting of drugs and a weak infrastructural base have been 
a huge disincentive for local production of drugs and growth of the sector, the activities of NAFDAC, one of the 
regulatory agencies, coupled with reforms taking place in the sector since 2001 have considerably addressed this 
situation. The impact of the reform is evident in increased firm profitability, re-investment and local 
manufacturing of drugs (23, 24). Reports show that primary, secondary packaging materials as well as about 25% 
of excipients are locally sourced (14). UNIDO report (14) indicates that no Nigerian pharmaceutical 
manufacturer has attained WHO cGMP (current Good Manufacturing Practice) or WHO prequalification 
requirements. However, recent developments have witnessed the endorsement of five pharmaceutical firms 
(Evans pharmaceuticals, May and Baker, SWIPHA, CHI Pharmaceuticals and Fidson HealthCare) for WHO 
prequalification (25). This is a significant effort towards pharmaceutical innovation development in Nigeria. 
Information is scanty on the state of pharmaceutical innovation in Nigeria despite NAFDAC reform initiatives 
since 2001 and other government intervention efforts geared towards increasing local production of drugs. 
Although not much has been done in delivering active pharmaceutical ingredient into the market, the production 
of HEMOXINTM or NICOSANTM for the Nigerian market is a modest demonstration of innovation success 
resulting from academia industry interaction and the evolution of a virile NIS in Nigeria. NICOSANTM is a non-
toxic, efficacious, phytopharmaceutical and anti-sickling patented drug clinically proven to reduce the sickling of 
the red blood cells of patients suffering from sickle cell diseases. The product is composed of extracts from Piper 
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guineeneses seeds, Pterocapus osun stems, Egenia cayophyllum flowers and Sorghum bicolor leaves, all 
indigenous to Nigeria and found in the wild or cultivated (26). The drug has been marketed in Nigeria since 2006 
under approval of the National Agency for Food and Drug Administration, a regulating agency of Federal 
Government of Nigeria, and given the status of Orphan Drug Designation the US and EU countries. The 
innovation success of NICOSANTM derives from interactions among key players in the Nigerian pharmaceutical 
sub-sector: research institute (NIPRD) and other stakeholders from the research community, a Nigerian Firm 
(Xechem Pharmaceuticals Nigeria Ltd) and the Nigerian Government with the active support of WHO. 
3.0  Methodology and Data Analysis 
A survey was conducted in Year 2011/2012 to examine the type and intensity of interactions between the 
Nigerian pharmaceutical firms and the academia (universities and research institutes, URIs). Two sets of 
questionnaires were administered for the academia and the pharmaceuticals firms, respectively. Eight (8) top-
ranked universities offering Pharmacy as a course and two (2) public research institutes were purposively 
targeted. Ten (10) researchers in each institution were randomly sampled. Also, twenty-five (25) pharmaceutical 
firms stratified into listed and non-listed firms on the Nigerian Stock Exchange were randomly sampled. Five (5) 
out of 8 listed firms and 20 non-listed firms were then targeted. Questionnaire retrieval rates were 91% and 100% 
for the academia and the industry, respectively. Collected data were analyzed by statistical tools.  
                                                                                                                                                                                               
4.0 Results and Data Interpretation 
4.1Quality of Research Personnel 
59% of the academic staff in the 8 Faculties of Pharmacy sampled had PhD degrees while 41% possessed M Sc. 
degrees (Fig. 1). In the Research Institutes, about 84% of the respondents surveyed holds Masters of Science 
degrees while the rest had PhD degrees (Fig. 2). Furthermore, staff distribution by rank indicate that about 4 out 5 
respondents were substantive lecturers from Lecturer I to the Professorial position, who could conduct research; 
about half of this number (43%) were senior researchers. In the research institutes, over 90% of the respondents 
were of the rank of Senior Research Officers to Chief Research Officers. These data indicate the availability of 
high quality human resources with the capability to conduct research and generate new knowledge useful for 
enhancing pharmaceutical innovation in Nigeria through interactions. 
Figure 1: Academic Qualifications of researchers in            Figure 2: Academic Qualifications of researchers in   
Universities               Research Institutes 
   4.2 Research Interests of Researchers
The scope of research conducted in the URIs covered mainly five (5) different areas of specializations, which are: 
Pharmacology, Clinical Pharmacy, Pharmaceutical Chemistry, Pharmacognosy, and Pharmaceutical Technology. 
Also, about 73% and 88.2% of researchers in the URIs, respectively carried out  applied research in Cancer, 
Tuberculosis, Asthma, High Blood Pressure, Malaria, HIV/AIDS, Diabetes and Sickle Cell anaemia.  
Malaria and Diabetes were the leading study areas of university researchers while HIV/AIDS in addition to 
Malaria and Diabetes constituted the leading research focus of RIs. For every 10 researchers in URIs, three 
carried out research on Malaria and about 2 focused on Diabetes. In RIs, 1 in 5 of researchers was involved in 
HIV/AIDS research.  It is noteworthy that the focus of researchers in the university was mainly on Malaria and 
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Diabetes while that of the RIs was more on Malaria, Diabetes and HIV/AIDS. The fact that Malaria and 
HIV/AIDS are listed among the diseases being targeted for control by the Millennium Development goals 
coupled with the high prevalence of Malaria in Nigeria could have attracted more researchers to focus on these 
diseases more than others.  
Furthermore, malaria research received the highest funding (23.3%) while Tuberculosis, Diabetes and Asthma 
received about 6.7% funding each (Fig. 3). However, about 66% of the funds received in the RIs were spent on 
Malaria and HIV/AIDS research (Fig. 4) which is a priority focus of the Nigerian Government. Other diseases 
such as cancer and Tuberculosis received 17% of R&D funding each. This shows that unlike the Universities 
who have liberties to utilize funds on curiosity-driven researches, Government-owned RIs could only conduct 
demand-driven researches in the areas of interest of Government. The study also revealed that the R&D activities 
of pharmaceutical researchers were supported by the provision of books/journal donations, travel aids/grants, 
staff exchange/fellowship programme, R&D facilities, sponsored participation at workshops and R&D 
grants/funding. 
Figure 3: Research areas University researchers received  funds    Figure 4: Research areas researchers in Research  
                   Institutes received research funds 
Other funding sources included Educational Trust Fund (13.91% and 19.3%) for Universities and Research 
Institutes, respectively. One notable profile of R&D funding sources was the high percentage of researchers URIs 
engaged in self-sponsored research. About 17% and 25.2% of respondents in universities and research institutes 
respectively derived major funding through self-sponsorship. A new funding mechanism, committing 1% GDP to 
R&D, included in the recently approved Science, Technology and Innovation (STI) policy for the country 
provides another option. It is noteworthy that only 0.22% of funds received by researchers in Universities were 
from Nigerian /indigenous pharmaceutical firms while researchers in the RIs were not funded by these firms. 
4.3Output of Research Activities of Researchers
R&D output that about 56% and 32% of researchers from the universities and RIs, respectively were majorly in 
from of journal publications (Figs. 5 and 6). Others outputs from the Universities and RIs were respectively in the 
form of: book publications (15.3%; 7.9%), technical reports (6.9%; 15.8%), production of products (7.6%; 
18.4%) & services (3.8%; 13.2%) and patents (2.3%; 7.9%). It is of importance that researchers in the RIs had 
varied R&D outputs than their research counterparts in the Universities.  
4.4 Profile of Pharmaceutical Firms
Out of the 25 companies surveyed, 15 (60%) were indigenously- owned, which confirms earlier reports of 60-
70% indigenous ownership of pharmaceutical firms in Nigeria (14). 9 (36%) firms were foreign – owned while 
only 1 (4%) was a multinational firm. Of the 5 quoted companies, 4 were foreign owned and 1 was a 
multinational. Only 40% i.e. 10 firms (5 quoted and 5 non-quoted) have R&D staff and reported conducting in-
house R&D activities. These 10 firms collectively have 4 Ph D and 16 Masters of Science Degree holders. 
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Figure 5: Research Output from Universities                   Figure 6: Research Output from Research Institutes
4.5 Drug Production: Sources of materials and Drugs of Interest 
The three (3) major sources of materials utilized for drug production according to the firms sampled were derived 
from: imported concentrates, local raw materials and a combination of imported concentrates and local raw 
materials. Study showed that a high percentage of respondents (61%) from the firms made use of a combination 
of imported concentrates and local raw materials. About 30% of respondents used imported concentrates as their 
only source of drug production materials while a small fraction (9%) of respondents affirmed that they used only 
local raw materials for their drug production. Although an earlier UNIDO report (14) indicated that no Nigeria 
pharmaceutical firm had the capability to produce API of generic and specialized drugs, this study shows a 
gradual increase in the local content of indigenous drug production in Nigeria. The study also showed that the 
pharmaceutical firms focused more on producing drugs for treating Malaria (28%), High Blood Pressure (23.3%), 
HIV/AIDS (14%), Diabetes (14%) and Asthma (11.6%). Other areas of focus of the firms for drug production 
were Tuberculosis (4.7%), Sickle cell and Ulcer with 2.3%. 
4.6 Academia-Industry Interactions 
4.6.1 Intensity of interactions
Of the pharmaceutical researchers surveyed twenty percent (20%) from universities (Figure 7) and seven (7%) 
RIs (Fig. 8) indicated strong interaction with Pharmaceutical firms. On the other hand, of the 25 pharmaceutical 
firms surveyed, sixteen (16%) indicated stronger interaction with pharmaceutical researchers in universities and 
RIs (Fig. 9). It is noteworthy that the respondents (16%) from pharmaceutical firms that claimed interactions with 
pharmaceutical researchers comprised four (4) out of the five (5) pharmaceutical firms listed on the Nigerian 
stock exchange. This connotes that it is only the major players in the Pharmaceutical Industry that were 
interacting/collaborating with pharmaceutical researchers. 
     
Figure 7: Interaction of University Researchers with Nigerian          Figure 8: Interaction of Researchers in Research    
Pharmaceutical Firms                           Institutes with Nigerian Pharmaceutical Firms
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Figure 10 indicates the areas of interaction of Nigerian pharmaceutical firm with the academia. This is majorly in 
product improvement and enhancement (50%), new product development (25%) and Production Process 
Enhancement/ Improvement (25%). It is important to note that only firms listed in Nigerian stock exchange 
interacted with the academia. 
4.6.2Frequency and benefits of Interaction of pharmaceutical firms with academia 
The frequency of interaction of pharmaceutical firms with universities and RIs, respectively. Data showed that 
pharmaceutical firms collaborated with university researchers daily, once a while and when the need arises with 
the frequencies of 17%, 50% and 33% respectively. On the other hand, pharmaceutical firms interacted with 
researchers in RI less frequently on weekly (20%), monthly (20%), once a while (20%) and only when the need 
arises (40%) basis. Some of the benefits derived from industry –academia linkage according to respondents 
included 57% knowledge sharing, 29% provision of Research facilities and 14% access to University students for 
internship. The obstacles respondents considered to be responsible for weak industry-academia collaboration 
included: inadequate funding (22%), lack of awareness (22%) and lack of information on initiation process for 
collaboration  (22%) Others were lack of information on academia capability (17%), poor infrastructure (9%) and 
lack of proximity (8%). 
4.7 Government support for Research-Industry interaction
The study revealed that both researchers and industrial firms claimed not to be aware of any Government policies 
fostering academia-industry interactions. The paper therefore argues that policies should be formulated to 
promote and foster academia-industry interactions.  
5.0 Conclusion and Recommendation 
5.1Conclusion 
This study identified the type, nature and intensity of academia-industry interactions in Nigeria’s pharmaceutical 
sub-sector.  
The study revealed that Nigeria’s pharmaceutical researchers are of high quality, with many of them possessing 
PhDs.  Key research activities are in Malaria, Diabetes and HIV/AIDS. Most pharmaceutical firms in Nigeria 
were found to be indigenously-owned; however, the firms quoted on the stock exchange are majorly foreign-
owned. R&D activities are concentrated within these foreign-owned firms; with the focus being on malaria, High 
Blood Pressure, HIV/AIDS, Diabetes and Asthma. Pharmaceutical research activities in Nigeria are primarily 
self-financed by the researchers –25% of researchers self-finance their research work). Other key financiers 
identified are International Development Agencies, the Federal Government and the Education Trust Fund. The 
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types of support included books/journal donations, travel aids/grants, staff exchange/fellowship programme, 
provision of R&D facilities, sponsored participation at workshops and R&D grants/funding. 
Academia-Industry interactions have been found to be severely limited. Less than 0.22% of funds received by 
researchers in Universities were from Nigerian indigenous pharmaceutical firms while no researcher in the 
Research Institutes received research funding from the firms. Only quoted firms acknowledged collaborations 
with researchers in URIs, whereas no indigenous firm in Nigeria acknowledged collaborations. Surprisingly, 20% 
of University researchers and 7% of RI researchers reported strong collaboration with Industry. Since, the 
industry reports limited collaboration with the researchers, it is only logical to conclude that Nigerian researchers 
collaborate with pharmaceutical firms outside Nigeria. It might also be logical to conclude that the direction of 
interaction is from the Industry to the researchers. This is because only one firm acknowledged collaboration with 
researchers and from a strategic management viewpoint that firms are at a critical advantage being able to 
determine which researcher it will collaborate with. 
It is significant to note that both researchers and industrial firms claimed not to be aware of Government policies 
fostering academia-industry interactions. 
5.2 Policy Recommendations 
i. Government needs to promote a strong national Pharmaceutical innovation ecosystem in order to 
stimulate robust academia-industry interactions in the sector.
ii. Government needs strong awareness campaigns to eliminate the zero awareness of government policies 
by the Academia and Industry.
iii. Robust funding mechanisms are required to reduce the percentage of researchers self-financing their 
research work. 
iv. Further research should be carried out in order to determine why indigenous firms do not engage 
researchers in the URIs. This could require new policies of government policies and could be seen as 
part of national security.
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